Adverse Event Risk Up for >90 Days Versus >30 Days of Corticosteroids for Eczema
By Lori Solomon HealthDay Reporter
WEDNESDAY, July 24, 2024 -- Use of oral corticosteroids for >90 days during one year is associated with a slightly increased risk of adverse events (AEs), according to a study published online July 19 in JAMA Network Open.
Yong Hyun Jang, M.D., Ph.D., from Kyungpook National University in Daegu, South Korea, and colleagues examined the association between long-term exposure to oral corticosteroids and occurrence of 11 AEs among adult patients with atopic dermatitis. Analysis included 164,809 cases and 328,303 controls.
The researchers found that 3.4 percent of cases and 3.2 percent of controls were exposed to oral corticosteroids for >30 days, while 0.4 percent in both groups were exposed to oral corticosteroids for >90 days. There was no increased risk of AEs with use of oral corticosteroids for >30 days (adjusted odds ratio, 1.00; 95 percent confidence interval, 0.97 to 1.04). However, the risk was higher with use of oral corticosteroids for >90 days (adjusted odds ratio, 1.11; 95 percent confidence interval, 1.01 to 1.23). For each cumulative or consecutive year of ever long-term use, there was a small elevation of risk for experiencing an AE.
"This study suggests that for patients with exacerbations of atopic dermatitis, limiting the duration of oral corticosteroid treatment to 90 days or less may limit adverse effects," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2024
Read this next
FDA Approves Zoryve for Atopic Dermatitis
THURSDAY, July 11, 2024 -- The U.S. Food and Drug Administration has approved Zoryve (roflumilast) cream, 0.15 percent, for the treatment of mild-to-moderate atopic dermatitis in...
Lebrikizumab Tied to Sustained Atopic Dermatitis Treatment Effect
TUESDAY, June 18, 2024 -- Lebrikizumab is associated with sustained effects for moderate-to-severe atopic dermatitis for up to week 52 following withdrawal of treatment, according...
1.5 Percent Ruxolitinib Cream Safe, Effective for Teens With Eczema
FRIDAY, May 31, 2024 -- Long-term intermittent use of ruxolitinib cream is well tolerated and provides disease control in adolescent patients with atopic dermatitis (AD)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.